Wednesday, September, 18, 2019 12:30:40

Biotech firm Tissue Regeneration Therapeutics Inc. (TRT) and Maryland based RoosterBio Inc. (RBI) have recently announced a crucial strategic alliance for advancing their common goal. Apparently, their aim is to accelerate the development of the Cellular Therapy and Regenerative Medicine fields.

This collaboration would allegedly be focusing on applying the unique, scalable bioprocess systems of RoosterBio to TRT’s key technology based on human umbilical cord perivascular cells (HUCPVCs). It is expected that both of the technology platforms would together create Regenerative Medicine’s newfound efficiencies by establishing a new level of perivascular stromal/stem cell producing productivity.

President and Chief Executive Officer of TRT, John Davies, DSc, mentioned that RoosterBio has established itself as a leader in human mesenchymal stem cells (hMSC) bioprocess systems, and TRT is eager to apply the cGMP production platforms of RoosterBio, which is scalable, to the umbilical cord perivascular cellular (TXP) patented technology of TRT.

Davies further said that the TXP technology of the company has unique benefits compared to different sources of mesenchymal cell and leveraging scalable production platforms of RoosterBio would accelerate TRT’s therapeutic programs. The strategic alliance would overall have a far reaching implications in the fields of Cellular Therapy and Regenerative Medicine.

Margot Connor, Chief Executive Officer of RoosterBio, was quoted saying that TRT has established itself as a leader in cord tissue perivascular cells, and RoosterBio would be collaborating for helping drive the cell manufacturing productivity in TRT’s unique technology platform. The company will be deepening its relationship with TRT, as RoosterBio has experienced great collaboration with TRT in the past few years.

For the uninitiated, RoosterBio, Inc. is focused towards accelerating the sustainable Regenerative Medicine industry’s development, one customer at a time. TRT has its focus on commercially developing their patented HUCPVC technology platforms, which includes engineered cells (eTXP) and culture expanded cells (TXP).